| About the author: |
Yu. A. Spivak, M. M. Potyazhenko, N. O. Lyulka, K. Ye. Vakulenko, Ya. V. Nos |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The course and consequences of acute myocardial infarction define concomitant diseases, particularly type 2 diabetes mellitus. The primary purpose was to estimate the efficiency of eplerenone in treating heart failure in patients with acute myocardial infarction and type 2 diabetes mellitus. Two groups and two subgroups were formed. Patients underwent general clinical examinations, troponin I, brain natriuretic peptide, and glycosylated hemoglobin. It was found that patients with myocardial infarction and type 2 diabetes mellitus have a significantly higher brain natriuretic peptide level in the blood. In using an optimized treatment scheme, a decrease in the level of the natriuretic peptide was noted in patients without diabetes during the third visit compared to the first and second. Significant differences in brain natriuretic peptide concentrations at different patient visits were found in patients with comorbidities (р=0.037). The appointment of eplerenone to standard therapy for patients with myocardial infarction with and without comorbid pathology has a positive effect on the efficiency of treatment and the course of heart failure, which is confirmed by a decrease in brain natriuretic peptide as one of the leading indicators of the effectiveness of treatment of heart failure progression. |
| Tags |
acute myocardial infarction,type 2 diabetes mellitus,heart failure,brain natriuretic peptide,eplerenone |
| Bibliography |
- Nakaz MOZ Ukrayiny No. 455 vid 02.07.2014 “Unifikovanyy klinichnyy protokol ekstrennoyi, pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) dopomohy khvorym na hostryy koronarnyy syndrom z elevatsiyeyu sehmenta ST”.
- Nakaz MOZ Ukrayiny No. 1118 vid 21 hrudnya 2012 roku “Unifikovanyy klinichnyy protokol pervynnoyi ta vtorynnoyi (spetsializovanoyi) medychnoyi dopomohy “Tsukrovyy diabet 2 typu”.
- Nakaz MOZ Ukrayiny No. 1936 vid 14.09.2021 “Unifikovanyy klinichnyy protokol ekstrennoyi, pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) dopomohy khvorym na hostryy koronarnyy syndrom z elevatsiyeyu sehmenta ST”.
- Boiko DI, Kachur RV, Ajala OM, Bodnar LA, Zhyvotovska LV. Characteristics of anxiety and depressive manifestations in patients with acute myocardial infarction taking into account their personal accentuations. Azerbaijan Medical Journal 2021: № 2:25–31. doi: 10.34921/amj.2021.2.004.
- Christenson ES, Collinson PO, Defilippi CR, Christenson RH. Heart failure biomarkers at point-of-care: current utilization and future potential. Expert Rev Mol Diagn. 2014;14(2):185–97. doi: 10.1586/14737159.2014.882772.
- Claret PG, Bobbia X, Roger C, Sebbane M, de La Coussaye JE. Review of point-of-care testing and biomarkers of cardiovascular diseases in emergency and prehospital medicine. Acta Cardiologica. 2015;70(5):515–515. doi:10.1080/AC.70.5.3110510.
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012, European Heart Journal 2012 33, 1787–1847 doi:10.1093/eurheartj/ehs104.
- Iqbal J, Fay R, Adlam D et al. Effect of eplerenone in percutaneous coronary intervention- treated post-myocardi- al infarction patients with left ventricular systolic dysfunc- tion: a subanalysis of the EPHESUS trial. Eur J Heart Fail 2014; 16: 685–91.
- McMurray J, Adamopoulos S, Anker S. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC // Eur. Heart J. 2012; 33: 1787–1847.
- Montalescot G, Pitt B, Lopez de Sa E et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double- Blind Reminder Study. Eur Heart J 2014; 35 (34): 2295–302.
- Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014;63(16):1593–603. doi: 10.1016/j.jacc.2014.01.014.
- Spivak YuA, Lyulka NO, Potyazhenko MM, Vakulenko KE, Dubrovinska TV. Biomarker and echocardiographic characteristics of heart failure in patients having acute myocardial infarction combined with diabetes mellitus of type 2. Wiadomości lekarskie. 2022; Vol. LXXV, ISSUE 4 PART 1: 759–764. doi: 10.36740/WLek202204102.
- Type 2 Diabetes Mellitus and Heart Failure. A Scientific Statement From American Heart Association and Heart Failure Socieety of America; 2019; 139:00–00. DOI:10.1161/CIR.0000000000000691.
- Vizzardi Е, Regazzoni V, Caretta G, Gavazzoni M, Sciatti E, Bonadei I, et al. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. Int J Cardiol Heart Vessel. 2014;3: 6–14. doi: 10.1016/j.ijchv.2014.03.005.
- Zhdan VN, Tkachenko MV, Babanina MYu, Kitura YeM, Kyrian OA. The most common causes of comorbidity in patients with rheumatoid arthritis. Family medicine. 2021. № 4 (96). 79–83. DOI: 10.30841/2307–5112.4.2021.249428.
|
| Publication of the article |
«World of Medicine and Biology» №3(81), 2022 year, 183-187 pages, index UDK 616.127-005.8.:616.379-008.64 |
| DOI |
10.26724/2079-8334-2022-3-81-183-187 |
